Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Entasis Therapeutics Holdings Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Entasis Therapeutics Holdings Inc market cap is $104.8M.
What is the 52-week high for Entasis Therapeutics Holdings Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Entasis Therapeutics Holdings Inc 52 week high is $3.88 as of September 16, 2025.
What is the 52-week low for Entasis Therapeutics Holdings Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Entasis Therapeutics Holdings Inc 52 week low is $1.40 as of September 16, 2025.
What is Entasis Therapeutics Holdings Inc stock price today?
Entasis Therapeutics Holdings Inc stock price today is $2.19.
What was Entasis Therapeutics Holdings Inc stock price yesterday?
Entasis Therapeutics Holdings Inc stock price yesterday was $2.20.
What is the PE ratio of Entasis Therapeutics Holdings Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Entasis Therapeutics Holdings Inc’s P/E ratio is -1.95.
What is the Price-to-Book ratio of Entasis Therapeutics Holdings Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Entasis Therapeutics Holdings Inc P/B ratio is 6.2951.
What is the 50-day moving average of Entasis Therapeutics Holdings Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Entasis Therapeutics Holdings Inc 50-day moving average is $2.07.